Last reviewed · How we verify
Levocarnitine Injection
At a glance
| Generic name | Levocarnitine Injection |
|---|---|
| Also known as | L-carnitine, Levocarnitine, Carnitine |
| Sponsor | Lee's Pharmaceutical Limited |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Levocarnitine for Reducing ESA Requirements in Hemodialysis Patients With Renal Anemia (PHASE4)
- Effect of L-Carnitine on Biomarkers of Myocardial Reperfusion Injury in Patients With STEMI (PHASE2)
- Effects of L-Carnitine in Amyotrophic Lateral Sclerosis Patients With CHCHD10 Mutations (PHASE4)
- Effects of L-carnitine Therapy on the Heart of Maintenance Hemodialysis Patients (PHASE4)
- A Clinical Trial to Assess the Effects of a Vitamin Shot on Energy Levels (NA)
- Effects of L-Carnitine Supplementation on Respiratory Distress Syndrome (PHASE4)
- Severe Male Factor Infertility Management (NA)
- Preventing Contrast-induced Nephropathy: Evaluating Hydration Strategies and L-carnitine Administration (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Levocarnitine Injection CI brief — competitive landscape report
- Levocarnitine Injection updates RSS · CI watch RSS
- Lee's Pharmaceutical Limited portfolio CI